Molecular dermatology research and development innovator HairDX today announced the results of a six month pilot study that presents, for the first time, evidence that genetic mechanisms may predict treatment response to Finasteride for postmenopausal female Androgenetic Alopecia (female hair loss).
“The double-blinded placebo study followed a small cohort of postmenopausal female patients suffering from Androgenetic Alopecia for a period of six months. Using a genetic technique patented by HairDX, we were able to identify women that benefited from Finasteride by experiencing a significant increase in hair counts”
“While Finasteride therapy in men has proven very effective in treating Androgenetic Alopecia (male pattern baldness), there have been frustratingly few therapies for the treatment of hair loss in women. Results of our pilot study are very encouraging, as it appears we have found a key piece of the genetic puzzle which identifies women who can benefit from Finasteride therapy in the same way men do. Our findings suggest these women actually have a female corollary to male pattern hair loss (Androgenetic Alopecia), and that is an important finding,” says Dr. Sharon Keene, Chief Medical Officer of HairDX. “Once these results are confirmed, it can usher in a new era of treatment for female Androgenetic Alopecia.”
“The double-blinded placebo study followed a small cohort of postmenopausal female patients suffering from Androgenetic Alopecia for a period of six months. Using a genetic technique patented by HairDX, we were able to identify women that benefited from Finasteride by experiencing a significant increase in hair counts,” says Andy Goren, Chief Executive Officer.
Genetic risk factors for long-COVID uncovered in a large multi-ethnic study